Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020371 · ClinicalTrials.gov registry record · Phase 1
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Neutropenia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00020371 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Neutropenia that has completed, run by National Cancer Institute (NCI). The trial reports 1 study location across 1 state.
The verdict
NCT00020371, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Neutropenia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have cancers that have not responded to previous therapy.
Conditions Studied
Interventions
- DRUG filgrastim
- DRUG BMS-247550
Study Locations (1)
Maryland
- Medicine Branch - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020371
The ClinicalTrials.gov registry entry for NCT00020371 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which filgrastim is the first listed.
NCT00020371 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00020371 about?
NCT00020371 is a clinical study titled "BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have cancers that have not responded to previous therapy.
What is the current status of trial NCT00020371?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-09.
What conditions does trial NCT00020371 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Neutropenia.
What interventions are being tested in trial NCT00020371?
The interventions under investigation include: filgrastim (DRUG), BMS-247550 (DRUG).
Who is sponsoring clinical trial NCT00020371?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00020371 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.